Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 5 years, the average EPS without NRIGrowth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 8 years, Rhelion Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 26.90% per year. The lowest was -184.40% per year. And the median was 0.00% per year.
Rhelion Life Sciences (STU:4YX0) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Rhelion Life Sciences EPS (Diluted) Related Terms
Rhelion Life Sciences EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Rhelion Life Sciences's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Rhelion Life Sciences's Diluted EPS for the fiscal year that ended in Mar. 2026 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhelion Life Sciences (STU:4YX0) has a EPS (Diluted) of €-0.00 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' EPS (Diluted) too high?
Rhelion Life Sciences' current EPS (Diluted) is €-0.00.
How does Rhelion Life Sciences' EPS (Diluted) compare to ZTS?
Rhelion Life Sciences' EPS (Diluted) of €-0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current EPS (Diluted) is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current EPS (Diluted) is €-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current EPS (Diluted) is €-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YX0 has been successfully added to your 
